Brief: Nextcell Pharma Updates On ProTrans Cell Therapy

NextCell Pharma AB

20/10/2022 12:33

Oct 20 (Reuters) - NextCell Pharma AB  NXTCL.ST :
    * PROTRANS CELL THERAPY PROVIDES LONG-TERM EFFECT IN TYPE-1
DIABETES WITH A SINGLE TREATMENT
    * TODAY ANNOUNCES THAT PATIENTS WHO 3 YEARS AGO WERE TREATED
WITH
PROTRANS IN PHASE II STUDY PROTRANS-2 HAVE MAINTAINED
SIGNIFICANTLY HIGHER ENDOGENOUS INSULIN PRODUCTION THAN PATIENTS
WHO RECEIVED PLACEBO, (63% COMPARED TO 23%)
    * RESULTS FROM INTERIM FOLLOW-UP STUDY PROTRANS-OBS SUGGEST
THAT
TREATMENT CHANGES COURSE OF DISEASE AND THAT EFFECT PERSISTS
OVER TIME

Source text for Eikon:  ID:nWkr75VwRK 
Further company coverage:  NXTCL.ST 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))